Cancer name Skin Cutaneous Melanoma
Cancer Type SKCM
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment DCR-BCAT
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Gene
Signature CCL4
Official Symbol CCL4
Mode of action TRAN_D_UP
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description qPCR measurements using total RNA isolated from thetumor show that DCR-BCAT caused a partial reduction in Ctnnb1 mRNA and a concomitant increase in the Ccl4 mRNA. As β-catenin has been previously shown to cause immune evasion,in part, by transcriptional repression of Ccl4, the alleviation of Ccl4 repression is associated with robust increases in the dendritic cell mRNA marker Itgae, which encodes CD103, and the cytotoxic T cell mRNA marker Cd8a.
PMID 30274786
Title RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade